15 Posts Not To Miss From Day 1 of ASCOBT24!
The ASCO Breakthrough (ASCOBT24) is being held in Yokohoma, Japan from 8th to 10th August co-hosted by the Japan Society of Clinical Oncology (JSCO) and Japanese Society of Medical Oncology (JSMO).
Here are some highlights from Day 1 of ASCOBT24 that you should not miss!
ASCOBT24 is here! Start of morning and map of where the approximate 750 attendees are from – emphasizing the global collaboration of driving knowledge to action and the spirit that Together We are Stronger than Cancer.
4 excellent talks on AI in the cancer clinic. I am amazed. These are all MDs with vast experience in artificial intelligence. A unique feature in ASCO Breakthrough.
Selfie with ASCO Asia Pacific Leadership Development Program members in Yokohama at ASCOBT24 – how many amazing early career oncology superstars can you fit in one elevator?
Happening NOW at ASCOBT24 Day 1. Proximity Therapy Drugs. Excellent overview and research activities on undruggable targets by Andrew Trister.
Asia Pacific Regional Council met in person prior to ASCOBT24 in Yokohama today! Together with ASCO Leadership including Robin Zon, we look forward to promoting quality oncology care, building collaborations and nuturing next generation leaders in our APAC region.
Precision Oncology is always an important topic embedded in Cancer Care and innovation today. Insightful kickoff by Daniel Tan taking a global lens to state of play in precision oncology and barriers. Love the Swiss chess concept!
Wrapped up the first day of ASCOBT24 at the Faculty and Collaborator’s Reception with our colleagues from the Japan Society of Clinical Oncology and Japanese Society of Medical Oncology where we were honored to be joined by Takeharu Yamanaka, the Mayor of Yokohama. A wonderful gathering. Together we are stronger than cancer!
Finally our poster presentation! ASCOBT24 is such a great conference to connect with experts with knowledge of population health in this region where many of US immigrants come from – divergent risks associated with liver cancer, underreporting issue in the region, and more!
Beauty is truth, truth beauty Thought provoking opening lecture on digital health: making sure the data used to generate AI tools have diverse populations, diverse voices, patient led Go beyond the restrictive bounds of clinical trials, our silos.
Dr. Daniel Nomura from UC Berkeley provided an overview of molecular-targeted drug development from chemistry standpoint at ASCOBT24.
Had a great time talking about our latest research and discussing future of cancer therapies with the panel! Now back to UC Berkeley to take out more oncogenic transcription factors!
Great discussion about how to apply LAURA study: How to treat patients with RT pneumonitis? High PDL1 in EGFR could just be constitutively activated – does not mean IO. Can we select patients who can stop lifelong ‘adjuvant’ osimertinib?
A drug, pacritinib, a JAK2i, used for myelofibrosis is now being evaluated for solid tumors through a different mechanism of action (tumor suppression with IRAK1 overexpression). Cool to see a transition from preclinical findings to actual drug development.
Impressive results of the combination of Olomorasib+pembro in patients with G12C tumors at ASCOBT24.
Dr Ying-Chun Shen summarises current ADC clinical application. Lots of questions remain.
For more updates on ASCOBT24, visit oncodaily.com